Skip to main content
POOLBEG PHARMA PLC logo

POOLBEG PHARMA PLC — Investor Relations & Filings

Ticker · POLB ISIN · GB00BKPG7Z60 LEI · 213800UZ8WJLWYHBFL52 IL Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2025-01-17 Director's Dealing
Country GB United Kingdom
Listing IL POLB

About POOLBEG PHARMA PLC

https://poolbegpharma.com/

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that develops and commercializes medicines for diseases with high unmet medical needs. The company's lead asset, POLB 001, is a treatment designed to prevent Cytokine Release Syndrome (CRS), a severe side effect associated with cancer immunotherapies, with the aim of making these treatments safer and more accessible. Poolbeg is also advancing an oral GLP-1 program for obesity, offering a patient-friendly therapeutic option. The company utilizes an artificial intelligence (AI)-led discovery platform that analyzes data from human challenge trials to identify novel drug targets. This AI-driven approach aims to accelerate target identification, reduce costs, and lower development risks.

Recent filings

Filing Released Lang Actions
Form 8.3 - Poolbeg Pharma plc
Director's Dealing Classification · 1% confidence The document is explicitly titled 'FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' and references 'Rule 8.3 of the Takeover Code'. This form is used to disclose insider dealings or significant ownership changes related to a takeover or merger situation. This type of disclosure, especially when mandated by a regulatory body like the Takeover Panel and disseminated via RNS (Regulatory News Service), falls under the category of insider trading or director/executive dealing disclosures, although it is specifically tied to takeover rules. Comparing the definitions, 'Director's Dealing (DIRS)' covers personal share transactions by directors/executives. While this is a specific type of dealing disclosure (Rule 8.3), it is the closest fit among the provided options for reporting personal security interests and transactions by an individual (Dr Patrick Mercer Reid) in relation to an offeree (Poolbeg Pharma PLC). The presence of 'RNS Number' and the distribution notice confirms it is a regulatory announcement, but DIRS is more specific than RNS or LTR.
2025-01-17 English
Form 8.3 - Poolbeg Pharma plc
Director's Dealing Classification · 1% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is used for 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' in the context of a takeover offer (Poolbeg Pharma plc). This type of filing relates to insider dealing/ownership disclosure during a takeover scenario. While it is a regulatory disclosure, it is highly specific. It is not a general regulatory announcement (RNS), nor is it a Director's Dealing report (DIRS), which typically refers to Form 3/4/5 filings under different rules. Given the specific nature concerning takeover rules and insider interests, and lacking a more precise category for 'Takeover Disclosure Form 8.3', the most appropriate classification among the provided options is 'Director's Dealing' (DIRS) as it concerns executive/insider transactions, or 'Regulatory Filings' (RNS) as a fallback. However, DIRS is often used broadly for insider transactions. Since this is specifically about interests in securities during a takeover bid, and DIRS is defined as 'Report of personal share transactions by company directors and executives (insider trades)', this is the closest fit for insider transaction reporting, even though the specific form (8.3) is unique to takeover codes. Given the options, DIRS captures the essence of insider transaction reporting better than the general RNS fallback, although RNS is also plausible if DIRS is strictly interpreted as only UK Model Code filings. Considering the context of insider trading disclosure, DIRS is selected as the best fit among the specific options.
2025-01-16 English
Form 8.3 - Poolbeg Pharma plc
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates to insider/significant shareholder dealings during a takeover or offer period. This specific content (disclosure of interests/dealings by a person connected to an offeror/offeree) aligns most closely with the category for Director's Dealing (DIRS), as it reports on personal share transactions/holdings by parties involved in a corporate action, although it is specifically mandated by Takeover Code rules rather than standard insider trading rules. However, looking at the provided definitions, 'Director's Dealing (DIRS)' is the closest fit for reporting personal share transactions by executives/insiders, even if the context here is a takeover disclosure (Form 8.3). Since it is a specific regulatory filing about share interests/dealings, DIRS is the most appropriate classification among the choices, as it is not a general earnings release (ER), annual report (10-K), or a general regulatory announcement (RNS) which is the fallback.
2025-01-15 English
Form 8.3 - Poolbeg Pharma plc
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' and references 'Rule 8.3 of the Takeover Code'. This form relates to disclosures required during a takeover or merger situation concerning interests in securities. While it is a regulatory disclosure, the specific nature of reporting insider/significant shareholder dealings during a takeover context aligns most closely with disclosures related to insider transactions or significant ownership changes, but the primary context here is the Takeover Code disclosure requirement itself. Given the options, 'Director's Dealing' (DIRS) covers personal share transactions by executives, and while this is a disclosure by a significant shareholder (Seneca Partners Limited) during a potential offer, the most fitting general category for mandatory regulatory disclosures that aren't standard periodic reports (10-K, IR) or specific announcements (DIV, ER) is often 'Regulatory Filings' (RNS) or, if focusing on the content, 'Major Shareholding Notification' (MRQ) or 'Director's Dealing' (DIRS). Since this is a specific disclosure mandated by the Takeover Code (Rule 8.3) regarding interests in securities during an offer, and it is not a standard director's dealing report (Form 4/3), nor a general major shareholding notification (which usually relates to crossing thresholds outside of a formal offer context), the most appropriate general classification for a specific, non-standard regulatory filing that doesn't fit elsewhere is RNS. However, Form 8.3 is a specific type of insider/significant holder disclosure related to an offer. If we must choose from the provided list, and considering it reports on interests/holdings (like MRQ) but is triggered by the Takeover Code, RNS serves as the best catch-all for specific regulatory forms not explicitly listed. Let's re-evaluate: DIRS is for directors' personal trades. MRQ is for crossing major shareholding thresholds. This is a disclosure under the Takeover Code. Since the document is a formal regulatory filing disseminated via RNS, and it doesn't perfectly match the definitions for DIRS or MRQ (which are usually for non-offer periods or different forms), RNS is the safest classification for a specific, non-standard regulatory document.
2025-01-14 English
Form 8.3 - Poolbeg Pharma plc
Director's Dealing Classification · 1% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates to insider/significant shareholder dealings, often in the context of a takeover offer, which falls under the category of Director's Dealing or insider transaction reporting. Comparing this to the provided definitions, 'Director's Dealing (Code: DIRS)' is the most appropriate fit, as it covers 'Report of personal share transactions by company directors and executives (insider trades)'. Although the document is a specific regulatory form (Form 8.3), the content directly relates to insider/director dealings.
2025-01-14 English
Form 8.3 - Poolbeg Pharma plc
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' related to an offer involving 'Poolbeg Pharma plc'. This type of mandatory disclosure concerning insider dealings or significant shareholdings during a takeover scenario is a specific regulatory filing. While it relates to director/insider activity (DIRS) or major shareholdings (MRQ), the specific context of a Takeover Code Form 8.3 disclosure is best categorized under the general regulatory filing umbrella, or if a more specific category exists. Since 'Director's Dealing' (DIRS) covers personal share transactions by executives, and this is a disclosure of interests/dealings related to a takeover, it fits closely with insider reporting. However, Form 8.3 is a very specific regulatory requirement under the Takeover Code, which often falls under the broader 'Regulatory Filings' (RNS) if a more precise code isn't available. Given the options, 'DIRS' covers personal share transactions by directors, and this is a disclosure by an individual (Michael Kelly) regarding his position in securities during an offer. Since the document is a formal regulatory filing (Form 8.3) mandated by the Takeover Code, and it details ownership/dealing by an individual, 'DIRS' is a strong candidate if we interpret it broadly as insider dealing disclosure, but 'RNS' is the safest fallback for specific, non-standard regulatory forms. Let's re-evaluate the definitions. DIRS is for 'Report of personal share transactions by company directors and executives (insider trades)'. This is a disclosure of a position/dealing by an individual (Michael Kelly) under the Takeover Code, which is a form of insider reporting. Given the highly specific nature of Form 8.3, which is mandatory disclosure during a takeover, it is a specific type of regulatory filing. Since there is no 'Takeover Disclosure' code, and it involves personal dealings/interests, DIRS is plausible, but RNS (General regulatory announcements/fallback) is often used for specific forms like this that aren't 10-K, ER, or IR. Given the content is a mandatory disclosure about an individual's interest in securities during an offer, it aligns most closely with the spirit of insider reporting (DIRS) or the general regulatory filing category (RNS). Because it is a formal, structured regulatory document (Form 8.3) and not a standard earnings or annual report, RNS is the most appropriate general regulatory classification.
2025-01-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.